6472 — Bora Pharmaceuticals Co Income Statement
0.000.00%
- TWD66.81bn
- TWD82.28bn
- TWD19.25bn
- 47
- 34
- 38
- 30
Annual income statement for Bora Pharmaceuticals Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,800 | 4,900 | 10,494 | 14,200 | 19,246 |
| Cost of Revenue | |||||
| Gross Profit | 704 | 1,672 | 2,913 | 6,991 | 7,710 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,186 | 3,854 | 8,572 | 8,951 | 14,114 |
| Operating Profit | 614 | 1,046 | 1,922 | 5,249 | 5,132 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 595 | 1,024 | 1,840 | 4,064 | 4,955 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 578 | 750 | 1,402 | 3,072 | 4,040 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 578 | 750 | 1,392 | 3,030 | 3,939 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 578 | 750 | 1,395 | 3,044 | 4,013 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.74 | 6.43 | 11.8 | 24.5 | 19.4 |
| Dividends per Share |